Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
free free
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Structural effects of oncogenic PI3Kalpha mutations Gabelli SB; Huang CH; Mandelker D; Schmidt-Kittler O; Vogelstein B; Amzel LMCurr Top Microbiol Immunol 2010[]; 347 (ä): 43-53Physiological activation of PI3Kalpha is brought about by the release of the inhibition by p85 when the nSH2 binds the phosphorylated tyrosine of activated receptors or their substrates. Oncogenic mutations of PI3Kalpha result in a constitutively activated enzyme that triggers downstream pathways that increase tumor aggressiveness and survival. Structural information suggests that some mutations also activate the enzyme by releasing p85 inhibition. Other mutations work by different mechanisms. For example, the most common mutation, His1047Arg, causes a conformational change that increases membrane association resulting in greater accessibility to the substrate, an integral membrane component. These effects are examples of the subtle structural changes that result in increased activity. The structures of these and other mutants are providing the basis for the design of isozyme-specific, mutation-specific inhibitors for individualized cancer therapies.|*Mutation[MESH]|Amino Acid Sequence[MESH]|Class I Phosphatidylinositol 3-Kinases[MESH]|Humans[MESH]|Molecular Sequence Data[MESH]|Neoplasms/*genetics[MESH]|Phosphatidylinositol 3-Kinases/*chemistry/*genetics[MESH] |